These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34001287)

  • 1. Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer.
    Eyck BM; van der Wilk BJ; Noordman BJ; Wijnhoven BPL; Lagarde SM; Hartgrink HH; Coene PPLO; Dekker JWT; Doukas M; van der Gaast A; Heisterkamp J; Kouwenhoven EA; Nieuwenhuijzen GAP; Pierie JEN; Rosman C; van Sandick JW; van der Sangen MJC; Sosef MN; van der Zaag ES; Spaander MCW; Valkema R; Lingsma HF; Steyerberg EW; van Lanschot JJB;
    Trials; 2021 May; 22(1):345. PubMed ID: 34001287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trial.
    Noordman BJ; Wijnhoven BPL; Lagarde SM; Boonstra JJ; Coene PPLO; Dekker JWT; Doukas M; van der Gaast A; Heisterkamp J; Kouwenhoven EA; Nieuwenhuijzen GAP; Pierie JEN; Rosman C; van Sandick JW; van der Sangen MJC; Sosef MN; Spaander MCW; Valkema R; van der Zaag ES; Steyerberg EW; van Lanschot JJB;
    BMC Cancer; 2018 Feb; 18(1):142. PubMed ID: 29409469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study.
    Noordman BJ; Spaander MCW; Valkema R; Wijnhoven BPL; van Berge Henegouwen MI; Shapiro J; Biermann K; van der Gaast A; van Hillegersberg R; Hulshof MCCM; Krishnadath KK; Lagarde SM; Nieuwenhuijzen GAP; Oostenbrug LE; Siersema PD; Schoon EJ; Sosef MN; Steyerberg EW; van Lanschot JJB;
    Lancet Oncol; 2018 Jul; 19(7):965-974. PubMed ID: 29861116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective cohort study on active surveillance after neoadjuvant chemoradiotherapy for esophageal cancer: protocol of Surgery As Needed for Oesophageal cancer-2.
    van der Zijden CJ; Lagarde SM; Hermus M; Kranenburg LW; van Lanschot JJB; Mostert B; Nuyttens JJME; Oudijk L; van der Sluis PC; Spaander MCW; Valkema MJ; Valkema R; Wijnhoven BPL;
    BMC Cancer; 2023 Apr; 23(1):327. PubMed ID: 37038138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol.
    Noordman BJ; Shapiro J; Spaander MC; Krishnadath KK; van Laarhoven HW; van Berge Henegouwen MI; Nieuwenhuijzen GA; van Hillegersberg R; Sosef MN; Steyerberg EW; Wijnhoven BP; van Lanschot JJ;
    JMIR Res Protoc; 2015 Jun; 4(2):e79. PubMed ID: 26121676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
    Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
    BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommon.
    Valkema MJ; Spaander MCW; Boonstra JJ; van Dieren JM; Hazen WL; Erkelens GW; Holster IL; van der Linden A; van der Linde K; Oostenbrug LE; Quispel R; Schoon EJ; Siersema PD; Doukas M; Eyck BM; van der Wilk BJ; van der Sluis PC; Wijnhoven BPL; Lagarde SM; van Lanschot JJB
    Br J Surg; 2023 Sep; 110(10):1381-1386. PubMed ID: 37418342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: A Systematic Review and Individual Patient Data Meta-analysis.
    van der Wilk BJ; Eyck BM; Hofstetter WL; Ajani JA; Piessen G; Castoro C; Alfieri R; Kim JH; Kim SB; Furlong H; Walsh TN; Nieboer D; Wijnhoven BPL; Lagarde SM; Lanschot JJBV
    Ann Surg; 2022 Mar; 275(3):467-476. PubMed ID: 34191461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched Study.
    van der Wilk BJ; Noordman BJ; Neijenhuis LKA; Nieboer D; Nieuwenhuijzen GAP; Sosef MN; van Berge Henegouwen MI; Lagarde SM; Spaander MCW; Valkema R; Biermann K; Wijnhoven BPL; van der Gaast A; van Lanschot JJB; Doukas M; Nikkessen S; Luyer M; Schoon EJ; Roef MJ; van Lijnschoten I; Oostenbrug LE; Riedl RG; Gisbertz SS; Krishnadath KK; Bennink RJ; Meijer SL;
    Ann Surg; 2021 Dec; 274(6):1009-1016. PubMed ID: 31592898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
    Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
    BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer.
    van der Wilk BJ; Eyck BM; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
    Dig Surg; 2019; 36(6):462-469. PubMed ID: 30227434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anatomical distribution of residual cancer in patients with oesophageal squamous cell carcinoma who achieved clinically complete response after neoadjuvant chemoradiotherapy.
    Chao YK; Chuang WY; Yeh CJ; Chang HK; Tseng CK
    Eur J Cardiothorac Surg; 2018 Jan; 53(1):201-208. PubMed ID: 28977486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active surveillance for clinical complete responders after chemoradiotherapy for oesophageal squamous cell carcinoma.
    De Pasqual CA; Weindelmayer J; Gervasi MC; Torroni L; Pavarana M; Cenzi D; Togliani T; Rossi R; Giacopuzzi S
    Br J Surg; 2024 Jan; 111(2):. PubMed ID: 38415879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients' preferences for treatment after neoadjuvant chemoradiotherapy for oesophageal cancer.
    Noordman BJ; de Bekker-Grob EW; Coene PPLO; van der Harst E; Lagarde SM; Shapiro J; Wijnhoven BPL; van Lanschot JJB
    Br J Surg; 2018 Nov; 105(12):1630-1638. PubMed ID: 29947418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 16. Surgeon's steering behaviour towards patients to participate in a cluster randomised trial on active surveillance for oesophageal cancer: A qualitative study.
    de Veer MR; Hermus M; van der Zijden CJ; van der Wilk BJ; Wijnhoven BPL; Stiggelbout AM; Dekker JWT; Coene PPLO; Busschbach JJ; van Lanschot JJB; Lagarde SM; Kranenburg LW
    Eur J Surg Oncol; 2023 Oct; 49(10):106935. PubMed ID: 37210275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoradiation versus oesophagectomy for locally advanced oesophageal cancer in Chinese patients: study protocol for a randomised controlled trial.
    Jia R; Yin W; Li S; Li R; Yang J; Shan T; Zhou D; Wang W; Wan L; Zhou F; Gao S
    Trials; 2019 Apr; 20(1):206. PubMed ID: 30971301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
    Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P
    BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in patients with upper GI malignancies managed by a strategy of chemoradiotherapy alone versus surgery.
    O'Connell L; Coleman M; Kharyntiuk N; Walsh TN
    Surg Oncol; 2019 Sep; 30():33-39. PubMed ID: 31500782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer.
    Noordman BJ; Wijnhoven BPL; Lagarde SM; Biermann K; van der Gaast A; Spaander MCW; Valkema R; van Lanschot JJB
    Dis Esophagus; 2017 Dec; 30(12):1-8. PubMed ID: 28881890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.